Type 1 Diabetes

Type 1 diabetes care has been transformed by closed-loop systems and disease-modifying therapy with growing recognition of beta-cell preservation. The session covers Tandem Control-IQ, Omnipod 5 and iLet bionic pancreas automated insulin delivery comparison, teplizumab (Tzield) for stage-2 prevention and screening implementation, type 1 diabetes screening rationale and feasibility, immunotherapy trials (rituximab, abatacept, golimumab), and pregnancy considerations. Discussion addresses CGM-integrated AID system outcomes, beta-cell encapsulated cell therapy (ViaCyte/Vertex VX-880), iPSC-derived beta cells, T1D in older adults, transition from pediatric to adult T1D care, and the equity considerations in advanced T1D technology access.